Ajanta Pharma Ltd announced strong financial results for the first quarter. For the reporting period ending June 30, the profit after tax (PAT) increased by 31 percentage points, reaching 334 crore rupees.
First Quarter Financial Performance
According to regulatory filings, in the same period last fiscal year, the company recorded a profit after tax of 255 crore rupees. The company's total operating income for the first quarter grew by 25 percent, amounting to 1,626 crore rupees compared to 1,303 crore rupees the previous year.
Sales Growth by Region
Significant growth was noted in the branded generics segment in India, where revenue increased by 24 percent, reaching 509 crore rupees from 409 crore rupees in the previous year. Furthermore, revenue from generics in the USA showed an impressive jump of 57 percent, rising to 487 crore rupees compared to 310 crore rupees the year before.


